PRESS RELEASE | Lykan Bioscience Appoints Industry Leader Patrick Lucy as President & CEO
• Patrick Lucy becomes President & Chief Executive Officer, and joins Lykan’s Board
of Director’s effective April 1st
• Anthony Rotunno assumes role of Founder & Executive Vice Chair
Hopkinton, MA, April 1, 2021 — Lykan Bioscience, a contract development and manufacturing services
organization and provider of the first true end-to-end solution for the manufacture of cell-based
therapies, today announced the appointment of Patrick Lucy as its President & Chief Executive Officer,
effective April 1, 2021. Patrick will assume day-to-day leadership of the Company and will also join
Lykan’s Board of Directors. Anthony Rotunno, Lykan’s current CEO, will assume the role of Founder
& Executive Vice Chairman and will continue to contribute to the growth of the Company.
“With his 44 years of experience in biopharmaceutical manufacturing, Anthony has consolidated that
vast experience in the founding of Lykan Bioscience and has established an outstanding team and cell
therapy manufacturing facility of the future,” said Lykan Bioscience Chairman Peter Crowley, “We look
forward to Patrick taking on the leadership of Lykan going forward. The Operating team and the Board
are both eager to continue to work with Anthony to support the business as he assumes his new role.”
“Patrick has made a significant impact since joining Lykan in January and has played a major role in
the company’s recent strategic decisions; I am confident in his ability to successfully drive the company
forward,” said Lykan Bioscience CEO Anthony Rotunno. “We congratulate Patrick on his transition to
his new role and look forward to his continued leadership.”
“Over the past three months, it has been a privilege to work with the Lykan partners, leadership team,
and Board of Directors”, said Patrick, “I am fully committed to Lykan’s goal of becoming the premier
patient-centric cell therapy contract manufacturer. I look forward to working with the entire Lykan team
and our current and future partners to achieve that goal on behalf of the patients that need these
therapies.”
About Lykan Bioscience
Lykan Bioscience is a privately held contract development and manufacturing services organization
located in Hopkinton, MA. The Lykan team offers decades of biopharmaceutical industry experience in
facility design, quality operations, and engineering, and the first true end-to-end solution provider for
cell-based therapies.
The company’s SMART Manufacturing™ purpose-built facility that has been uniquely designed to fully
integrate cGMP principles and advanced software solutions. Our software application platform allows
for timely access to data, logistics, and expertise in driving treatments from clinical production through
to commercial manufacturing.
Lykan Bioscience and our clients are Transforming the Future Together™, as we work collaboratively
to provide new life-saving therapies to patients worldwide. For further information, please visit
www.lykanbio.com
###
Media Contact:
Kim Yang
Marketing Director
kim.yang@lykanbio.com